Table 3.

Correlation between EGFR molecular analysis and clinical variables

EGFR mutation (n = 92)*
EGFR amplification (n = 88)
EGFR expression (n = 75)
n (%)Pn (%)Pn (%)P
Age
    <6012/44 (27.3)0.80416/43 (37.2)0.49026/37 (70.3)0.742
    ≥6012/48 (25.0)20/45 (44.4)28/38 (73.7)
Sex
    Male10/57 (17.5)0.01718/54 (33.3)0.06936/47 (76.6)0.251
    Female14/35 (40.0)18/34 (52.9)18/28 (64.3)
Stage
    IIIB3/8 (37.5)0.4424/7 (57.1)0.3634/7 (57.1)0.358
    IV21/84 (25.0)32/81 (39.5)50/68 (73.5)
Histology
    Adenocarcinoma18/57 (31.6)0.12625/56 (44.6)0.34634/47 (72.3)0.932
    Others6/35 (17.1)11/32 (34.4)20/28 (71.4)
ECOG performance status
    0-122/84 (26.2)0.94233/80 (41.3)0.83748/67 (71.6)0.842
    2-32/8 (25.0)3/8 (37.5)6/8 (75.0)
Smoking
    Never smoker13/38 (34.2)0.13717/37 (45.9)0.41335/44 (79.5)0.083
    Smoker11/54 (20.4)19/51 (37.3)19/31 (61.3)
Erlotinib
    First line3/14 (21.4)0.6667/14 (50.0)0.4516/8 (75.0)0.842
    ≥Second line21/78 (26.9)29/74 (39.2)48/67 (71.6)
Skin rash
    Yes18/72 (25.0)0.65225/69 (36.2)0.08942/59 (71.2)0.763
    No6/20 (30.0)11/19 (57.9)12/16 (75.0)
  • * Exon 18, 19, or 21.